| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| EMN39 | 25-31 | Adults who have been newly diagnosed with multiple myeloma |
EMN39 is a clinical trial for people with newly diagnosed multiple myeloma who cannot undergo a stem cell transplant, designed to find out whether a newer treatment called linvoseltamab works better and is as safe as the current standard treatment in helping patients achieve deeper, longer-lasting control of their cancer. |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| HOVON 177 (EVOLVE-2) | 24-92 | Newly diagnosed with a type of blood cancer called acute myeloid leukemia (AML), have specific genetic changes (called NPM1 mutations or KMT2A rearrangements), and are not well enough to receive intensive chemotherapy |
The HOVON 177 (EVOLVE-2)study is testing whether adding a new targeted medicine called revumenib to standard AML treatment can help people live longer and keep their leukemia under control for longer. |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| HO173: EVOLVE-1 | 24-91 | For adults who have recently been diagnosed with acute myeloid leukemia (AML), or a closely related condition called MDS/AML, whose cancer has an IDH1 gene mutation and who are not suitable for intensive chemotherapy |
The HOVON 173 study is testing whether adding the medicine venetoclax to standard treatment can help people with IDH1-mutated AML live longer and keep their leukemia under control for longer |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| RADAR | 25-28 | Adults who have early-stage Hodgkin lymphoma, have not started treatment yet, and do not have symptoms or disease features that suggest a more advanced form of the illness. |
The RADAR study is testing whether a newer treatment approach for people with newly diagnosed early-stage Hodgkin lymphoma can improve cure rates while reducing some of the side effects associated with current standard treatment |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| CELESTIAL-RRCLL (BGB-11417-303) | 26-48 | A cancer of a type of white blood cell that has either come back after treatment (relapsed) or has not responded adequately to treatment (refractory), causing abnormal lymphocytes to build up in the blood, bone marrow, and lymph nodes. |
The CELESTIAL-RRCLL (BGB-11417-303) clinical trial aims to find out whether a new treatment containing sonrotoclax can keep chronic lymphocytic leukemia/small lymphocytic lymphoma under control for longer, and safely, compared with a currently approved treatment in people whose disease has returned or stopped responding to previous therapy. |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| MK2140-011 | 25-26 | A form of blood cancer called DLBCL, specifically the GCB subtype, which tends to respond better to treatment. |
This clinical trial is testing two different drug combinations to treat a type of blood cancer called DLBCL, specifically the GCB subtype. It compares a newer medicine called zilovertamab vedotin with an existing one called polatuzumab vedotin. Both are given alongside standard chemotherapy drugs. The goal is to see which combination works better at shrinking the cancer, keeping it from coming back, and causing fewer side effects. People in the trial have not yet received treatment for their DLBCL. By studying these options, researchers hope to improve outcomes and offer better choices for patients with this form of lymphoma. |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| CLL18 / MOIRAI | 24-34 | previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) |
The CLL18 (MOIRAI) trial is testing different combinations of cancer drugs to treat chronic lymphocytic leukemia (CLL) in people who haven’t had treatment before. It compares fixed-duration treatments with a personalized approach that stops treatment early if the cancer becomes undetectable. The goal is to find the most effective and safest way to treat CLL while minimizing side effects and improving quality of life. |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| ALIDHE | 24-27 | IDH1m acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy. |
The purpose of this study is to learn more about the safety and efficacy of the medication |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| GIV-IN PV Trial | 24-99 | JAK2V617F-positive high-risk Polycythemia Vera patients |
The goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in Jak2V617F-positive high-risk polycythemia vera patients. |
